Consensus Zai Lab Limited Hong Kong S.E.

Stocks

9688

KYG9887T1168

Pharmaceuticals

Market Closed - Hong Kong S.E. 01:38:17 13/11/2026 pm IST			5-day change	1st Jan Change
20.24 ^HKD	-3.71%		+10.24%	+48.28%

13/11	Zai Lab Limited - Special Call
13/11	Zai Lab Says Experimental Drug Reduced Activity of Protein Linked to Atopic Dermatitis by at Least 90%	MT

6a2cd17c75c4c11c51b67b3d7.WJjIR41wuE_XZM8JaA5oKTf1cbP9Bl-it-dZM8J6yOY.YciYD8A_4SyILatxJ3g3S02wSYHEVDrD3qoteKE8l4UItY4p-gn0fLRQpA~8c1f4f5406ed596a1597beb0dfc15cea

Analysts' recommendations: Zai Lab Limited

06/11	Zai Lab Q3 Performance Meets Expectations With Pivotal 2027 Ahead, UBS Says	MT
07/01	UBS Initiates Zai Lab at Buy With $35 Price Target	MT
05/11	Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study	RE
05/11	Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study	CI
13/25/13	JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating	MT
03/25/03	BofA Securities Downgrades Zai Lab to Neutral	MT
12/24/12	JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating	MT
14/23/14	Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target	MT
26/23/26	Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating	MT
26/23/26	Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating	MT
10/23/10	Cantor Fitzgerald Initiates Coverage on Zai Lab With Overweight Rating, $70 Price Target	MT
12/23/12	BofA Adjusts Price Target on Zai Lab to $62.50 From $75, Maintains Buy Rating	MT
11/23/11	Citigroup Adjusts Price Target on Zai Lab to $130 From $138, Keeps Buy Rating	MT
16/23/16	JPMorgan Adjusts Price Target on Zai Lab to $70 From $79, Maintains Overweight Rating	MT
18/22/18	JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating	MT
11/22/11	Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating	MT
09/22/09	Citigroup Adjusts Zai Lab's Price Target to $199 From $193, Reiterates Buy Rating	MT
26/22/26	CSPC Pharma Shares Fall After Weaker 1Q Profit	DJ
12/22/12	Citigroup Adjusts Zai Lab Price Target to $193 From $198, Maintains Buy Rating	MT
11/22/11	SVB Securities Adjusts Zai Lab Price Target to $95 From $101, Maintains Outperform Rating	MT
06/22/06	Guggenheim Adjusts Price Target for Zai Lab to $85 From $134, Maintains Buy Rating	MT
21/22/21	SVB Leerink Adjusts Zai Lab Price Target to $101 From $102, Maintains Outperform Rating	MT
04/22/04	JPMorgan Lowers Zai Lab's Price Target to $112 From $136, Maintains Overweight Rating	MT
03/22/03	Analyst recommendations: Acushnet, Bristol-Myers Squibb, Intel, iQIYI, Polymetal...
03/22/03	SVB Leerink Adjusts Zai Lab Price Target to $102 From $194, Maintains Outperform Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+1.38%
	JOHNSON & JOHNSON					-2.22%
	ABBVIE INC.					+5.69%
	ROCHE HOLDING AG					-2.05%
	MERCK & CO., INC.					+9.32%
	NOVARTIS AG					-3.71%
	ASTRAZENECA PLC					+16.57%
	AMGEN INC.					-7.27%
	GILEAD SCIENCES, INC.					+3.98%
	Average					+2.41%
	Weighted average by Cap.					+1.97%